Heartseed 2024/7/30 東証グロースへ上場

6 known investors

Heartseed develops cardiac regenerative medicine, creating heart muscle cells from iPS cells for transplantation to treat heart failure, with its lead pipeline HS-001 nearing clinical trials. The company targets patients with heart failure caused by conditions such as myocardial infarction, with reference markets in Japan and the US.

BiotechHealthtechMedical Devices